

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use many sheets as necessary) Sheet <u>1</u> of <u>2</u>		Application Number	10/659,708
		Filing Date	09/11/2003
		First Named Inventor	Brian Leyland-Jones
		Group Art Unit	1646
		Examiner Name	Unassigned
		Attorney Docket Number	057491-0758

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
Z.F.	A1	BUTT et al., "Insulin-like Growth Factor-binding Protein-3 Modulates Expression of Bax and Bcl-2 and Potentiates p53-independent Radiation-induced Apoptosis in Human Breast Cancer Cells," <u>The Journal of Biological Chemistry</u> , December 15, 2000, pp. 39174-39181, Vol. 275, No. 50, The American Society for Biochemistry and Molecular Biology, Inc., USA	
Z.F.	A2	Database USPT on WEST, SPENCER et al., "Therapeutic uses of human somatomedin carrier proteins," US Patent No. 5681818, October 28, 1997	
Z.F.	A3	FOWLER et al., "Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Potentiates Paclitaxel-Induced Apoptosis in Human Breast Cancer Cells," <u>Int. J. Cancer</u> , 2000, pp. 448-453, Vol. 88, Wiley-Liss, Inc.	
Z.F.	A4	GILL et al., "Insulin-like Growth Factor-binding Protein (IGFBP-3) Predisposes Breast Cancer Cells to Programmed Cell Death in a Non-IGF-dependent Manner," <u>The Journal of Biological Chemistry</u> , October 10, 1997, pp. 25602-25607, Vol. 272, No. 41, The American Society for Biochemistry and Molecular Biology, Inc., USA	
Z.F.	A5	GIULIANO et al., "Induction of Apoptosis in Human Retinoblastoma Cells by Topoisomerase Inhibitors," <u>Investigative Ophthalmology &amp; Visual Science</u> , July 1998, pp. 1300-1311, Vol. 39, No. 8, Association for Research in Vision and Ophthalmology	
Z.F.	A6	HOLLOWOOD et al., "IGFBP-3 Prolongs the p53 Response and Enhances Apoptosis Following UV Irradiation," <u>Int. J. Cancer</u> , 2000, pp. 336-341, Vol. 88, No. 3, Wiley-Liss, Inc.	
Z.F.	A7	LEAL et al., "The Type V Transforming Growth Factor $\beta$ Receptor is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor," <u>The Journal of Biological Chemistry</u> , August 15, 1997, pp. 20572-20576, Vol. 272, No. 33, The American Society for Biochemistry and Molecular Biology, Inc., USA	
Z.F.	A8	LEE et al., "Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells," <u>Biochemical and Biophysical Research Communications</u> , 2002, pp. 480-486, Vol. 294, Academic Press, Elsevier Science (USA)	
Z.F.	A9	LEE et al., "Insulin-like Growth Factor Binding Protein-3 Inhibits the Growth of Non-Small Cell Lung Cancer," <u>Cancer Research</u> , June 15, 2002, pp. 3530-3537, Vol. 62	
Z.F.	A10	LU et al., "Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)," <u>Journal of the National Cancer Institute</u> , December 19, 2001, pp. 1852-1857, Vol. 93, No. 24	
Z.F.	A11	OH et al., "Demonstration of Receptors for Insulin-like Growth Factor Binding Protein-3 on Hs578T Human Breast Cancer Cells," <u>The Journal of Biological Chemistry</u> , December 15, 1993, pp. 26045-26048, Vol. 268, No. 35, The American Society for Biochemistry and Molecular Biology, Inc., USA	

Examiner Signature	<i>Zohub Fay</i>	Date Considered	9/16/04
--------------------	------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE				Application Number	10/659,708
STATEMENT BY APPLICANT				Filing Date	09/11/2003
(use as many sheets as necessary)				First Name of Inventor	Brian Leyland-Jones
				Group Art Unit	1646
				Examiner Name	Unassigned
				Attorney Docket Number	057491-0758
Sheet	2	of	2		

[illegible]

Examiner Signature	<i>Eohuf Fay</i>	Date Considered	10/16/04
-----------------------	------------------	--------------------	----------

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.